---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000214"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:18:46.708739+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances

## Summary
- Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.
- Revenue Q4 $7.2M, FY $82.0M, down $70.3M YoY due to lower CSL collaboration milestones and supply activity.
- Cash $232.8M at Dec 31, 2025; cash runway extended into Q2 2028.
- ARCT-032 (CF) third cohort (15 mg, 28 days) safe; 12-week Phase 2 study to start H1 2026.
- KOSTAIVE COVID-19 vaccine granted UK MHRA approval in Jan 2026; BARDA pandemic flu vaccine shows durable immune response.

## SEC filing metadata
- accession: 0001193805-26-000214
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/0001193805-26-000214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/e665201_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000214
- JSON: https://secwatch.observer/filing/0001193805-26-000214.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.